DOD Breast Cancer Clinical Translational Research Award | Apply Online

Opportunity Summary:

The DOD Breast Cancer Clinical Translational Research (CTR) Award, offered through the Department of the Army and administered under the Breast Cancer Research Program (BCRP), is designed to push breast cancer research beyond promising laboratory findings and into real-world patient testing. The main goal is to produce meaningful improvements over current prevention and treatment approaches, especially projects aimed at preventing primary breast cancer, reducing recurrence, or stopping progression to metastatic disease. In practical terms, the program is looking for studies that are ready to translate strong preclinical results into clinical settings where they can begin to influence how breast cancer is managed.

This opportunity specifically targets advanced translational research that directly leads into a prospective clinical trial that will actually occur during the award period. Applicants are expected to be close to the clinic already, not at the early discovery stage. Proposed projects can come from a research team that has developed a therapy, diagnostic, or intervention internally, or they can be built around partnerships with industry, such as using an existing company platform or candidate drug that is ready for clinical evaluation. Either way, the application has to show that the team can realistically complete both the remaining translational steps and an early phase clinical trial within the proposed timeline.

A key feature of the CTR Award is how strongly it emphasizes readiness and feasibility. Applications must include preliminary data along with a clear scientific and clinical rationale showing why the approach is likely to work and why it should be tested in people now. Because the translational phase is relatively short, applicants are expected to already have proof of concept and demonstrated efficacy in an in vivo model at the time they apply. This requirement makes it clear that the award is meant for projects that have moved past basic plausibility and have generated credible preclinical evidence suggesting potential benefit.

The clinical trial component must be well planned and statistically sound. Proposals need a clear experimental design and a properly powered statistical plan, meaning the trial should enroll an adequate number of participants to answer its primary questions in a meaningful way. Reviewers will also expect applicants to show that they have access to the necessary patient population to complete enrollment and generate interpretable outcomes. In other words, the proposal must demonstrate that the clinical environment, recruitment pathways, and infrastructure are in place so the trial can be executed successfully rather than remaining aspirational.

In terms of award mechanics, this funding opportunity (W81XWH-12-BCRP-CTR) was posted on February 23, 2012, with an application closing date of August 15, 2012, and it was later archived on September 14, 2012. The funding instrument is listed as a cooperative agreement and grant, within the federal research and development category. The program anticipated making about three awards, with an estimated total funding amount of $9,000,000, and it did not require cost sharing or matching. Eligibility was described as unrestricted, meaning a wide range of organizations could apply as long as they met any additional requirements stated in the full announcement.

Overall, the CTR Award is best understood as a bridge between strong preclinical success and early clinical validation. It is aimed at teams that can show they already have convincing in vivo results, have a credible plan to complete the remaining translational work quickly, and are prepared to run a prospective early phase clinical trial with appropriate statistical power and access to participants. For applicants, the central challenge is proving that the project is not only scientifically compelling, but also operationally ready to deliver clinical results within the award period. For questions or access issues related to the full announcement, the listing provides the CDMRP Help Desk contact information at 301-682-5507 and help@cdmrp.org.

Browse more opportunities from the same agency: Dept. of the Army USAMRAA

Browse more opportunities from the same category: Science and Technology and other Research and Development

Next opportunity: Social Science Research on Indigent Defense

Previous opportunity: DOD Breast Cancer Impact Award

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for W81XWH 12 BCRP CTR

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (W81XWH 12 BCRP CTR) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 12 BCRP CTR", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.